CHAI
Commodity AI firm ChAI has begun a project with BASF-YPC to forecast olefin prices including Ethylene, Propylene and Butadiene. BASF-YPC Company Limited is a large-scale petrochemical 50:50 joint venture between the world's two largest chemical companies BASF and Sinopec. ChAI provides BASF-YPC with Olefin price forecasts to support the company’s market intelligence and enhance its feedstock cost management.
ChAI is a data-driven market insights tool for companies exposed to commodity prices. ChAI uses proprietary AI technology to provide forecasts that update daily to enable companies to understand raw material price changes in their cost base fully. This information can help companies to enhance their hedging strategies, enable more accurate budgeting and justify purchasing decisions.
ChAI is democratizing the tools, techniques and data that have long given speculators a competitive edge: combining state-of-the-art AI techniques with exciting new alternative data sources to reduce the risk in physical supply chains. Their innovation helps better mitigate shocks to company cash flows and P&Ls – enabling businesses to plan better for the future and be more resilient.
Tristan Fletcher, CEO at ChAI, said: “It is a real honour to be able to serve two of the world’s largest and most prestigious chemicals companies, forecasting the raw materials in their cost base.”
Website: www.chaipredict.com
Linkedin: www.linkedin.com/company/chaipredict
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221214005078/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Shield and PwC UK Forge Strategic Collaboration to Deliver Future-Ready Communications Compliance18.9.2025 08:00:00 CEST | Press release
Collaboration brings together Shield's AI-first platform with PwC's surveillance expertise to deliver measurable compliance outcomes Shield, a leading AI platform for digital communication governance and archiving, today announced a collaboration with PwC UK, one of the world’s most trusted professional services firms. The alliance brings together Shield’s unified, cloud-native solution with PwC’s specialist expertise in communications surveillance delivery, regulatory compliance and complex programme execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917394739/en/ Shield and PwC launch a strategic collaboration to modernize eComms surveillance with AI-driven compliance solutions for financial institutions. The collaboration is designed to support institutions as they modernise their approach to communications monitoring, helping them implement an advanced and proactive risk management approach at scale and with co
Almirall Presents Long‑Term Results from First Real‑World Dermatology Study Using WHO‑5 Well‑Being Index as Primary Endpoint in the treatment of Psoriasis at EADV 202518.9.2025 08:00:00 CEST | Press release
Results of the POSITIVE study assessing the treatment with tildrakizumab showed sustained improvements in skin clearance, psychological well-being, and improved partner quality of life in adults with moderate-to-severe psoriasis over two years.POSITIVE is the first real-world evidence (RWE) study in dermatology to use the WHO-5 Well-Being Index as a primary endpoint, complementing traditional measures of skin disease (PASI, PGA), quality of life (DLQI), with the assessment of psychological well-being, marking a paradigm shift towards holistic management of psoriasis.The POSITIVE study highlights Almirall’s leadership in advancing patient-centred dermatology aligned with the WHO’s health definition and recent resolution on skin diseases.Almirall’s extensive scientific contributions to EADV 2025 include 44 abstracts across key dermatological conditions including atopic dermatitis, psoriasis, actinic keratosis, and hidradenitis suppurativa, and two expert-led symposia. Almirall, S.A. (ALM
Curatis: FDA Minutes Confirm Positive Outcome of Meeting on 9. September 2025 – Corticorelin on Track for Phase 318.9.2025 07:00:00 CEST | Press release
Curatis Holding AG (SIX:CURN) received the official minutes from the FDA meeting which took place on 9. September. Based on the totality of the feedback and discussions, Curatis can proceed as planned with the clinical development of corticorelin. Corticorelin is under development as a novel treatment intended to reduce or even eliminate steroid use and associated toxicities thereby potentially impacting the quality of life of patients suffering from peritumoral brain edema (PTBE) associated with metastatic (secondary) brain tumors. The virtual meeting with the FDA provided the opportunity to discuss the clinical development plan for corticorelin and encompassed CMC (Chemistry, Manufacturing and Control), nonclinical and clinical aspects. The offical FDA minutes which Curatis received after publication of the half year results reflect the positive outcome. Curatis may proceed without delay to a regulatory submission supporting a pivotal study in patients suffering from PTBE secondary t
Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay18.9.2025 07:00:00 CEST | Press release
Cetaphil's new Skin Activator Hydrating & Firming Line harnesses a proprietary formula, co-created with dermatologists and offering targeted, high-performance skincare designed to improve the appearance of skin affected by dermatoporosis The line’s new Skin Activator technology uses microdosed alpha hydroxy acid (AHA) and encapsulated centella asiatica (CICA) to wake up sleeping surface skin cells To help bring this segment-defining product line to life, Cetaphil is partnering with acclaimed actress, director, and advocate, Mariska Hargitay, a powerful voice in embracing beauty at every stage Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface
Merck Opens Climate-Neutral €150 Million Filter Manufacturing Facility in Ireland18.9.2025 07:00:00 CEST | Press release
Part of company’s €440 million investment in Ireland, strengthens Merck’s in-region-for-region supply resilienceMerck’s first climate-neutral manufacturing facility, powered by 100 percent renewable electricityNew Blarney site in Cork, Ireland expands filter manufacturing capacity, creating more than 200 jobs by 2028 Merck, a leading science and technology company, has opened today its €150 million filter manufacturing facility in Blarney Business Park, Cork, Ireland. The site is Merck’s first manufacturing facility designed for full climate-neutral operations, marking a key milestone in the company’s ambition to achieve climate neutrality by 2040. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250917767425/en/ Merck's new Blarney site in Cork expands company's filter capacity, creating 200+ jobs by 2028 The 3,000-square-meter cleanroom facility supports global demand for critical filtration products used in the manufacturin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom